ALTERNATIF LINK PLATINUM

platinum 789Keynote-789. KEYNOTE-789 was a randomized, double-blind phase 3 study. 18 It was desned to evaluate the addition of pembrolizumab to platinum-based chemotherapy inConclusion. With ∼4 years of follow-up, pembrolizumab plus pemetrexed-platinum continued to provide OS and PFS benefit vs pemetrexed-platinum alone in patients with